Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
These results represented a breakthrough in obesity pharmacotherapy and led to FDA approval of Zepbound
The study's results suggested that the various IGF-1 analogs, including Receptor Grade IGF-1 LR3, appear to potentially reverse adverse myostatin and prevent apoptosis
On December 19, 2025, Eli Lilly announced that retatrutide produced 28.7% body weight loss in the Phase 3 TRIUMPH-4 trial
Constantly losing and gaining weight called weight cycling or yo-yo dieting leads to adverse health outcomes, according to the Endocrine Society
GLP-1 agonists are a whole class of drugs with various generic and brand names semaglutide (Ozempic/Wegovy/Rybelsus), dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Saxenda/Victoza) and tirzepatide (Mounjaro/Zepbound) to name a few
